The second issue of the GAPP Studies’ newsletter focuses only on GABA-1 study and includes an overview on:
• regulatory status – agreements – sites activation – readiness to patients’ enrolment;
• actual patients’ enrolment status among the active investigational sites and identified issues;
• nonclinical safety study;
• suggestions for clinical staff.
You can donwnload the Newsletter here.
